The GH Secretagogue Stack: CJC-1295 (No DAC) + Ipamorelin

The GH secretagogue stack pairs CJC-1295 (no DAC)—a modified growth hormone-releasing hormone (GHRH) analog—with ipamorelin, the first selective growth hormone secretagogue. Together, they stimulate pulsatile growth hormone release through two complementary receptor pathways at the anterior pituitary: the GHRH receptor (Gs/cAMP-coupled) and GHS-R1a (Gq/calcium-coupled). Published research confirms that simultaneous activation of both pathways produces a synergistic GH response significantly greater than the additive sum of individual responses.

This guide evaluates both the mechanistic foundation—which is genuinely strong—and the clinical evidence gap between “elevated growth hormone” and “meaningful body composition or recovery outcomes.” The pharmacology is sound. The outcomes data is where the community’s expectations outpace the evidence.

What Is the GH Secretagogue Stack?

↑ Back to contents

The GH secretagogue stack combines two peptides that increase growth hormone release from the pituitary gland through different receptor mechanisms:

CJC-1295 (no DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH). It consists of a modified 29-amino-acid GHRH sequence with four amino acid substitutions that improve metabolic stability. It activates the GHRH receptor on pituitary somatotrophs, triggering cAMP-dependent GH synthesis and release. Its plasma half-life is approximately 30 minutes, producing discrete GH pulses rather than sustained elevation.

Ipamorelin is a pentapeptide growth hormone secretagogue that activates GHS-R1a (the ghrelin receptor) on the same somatotroph cells. Unlike older GHS-R1a agonists (GHRP-2, GHRP-6, hexarelin), ipamorelin is the first selective GH secretagogue: it produces robust GH pulses without elevating cortisol or prolactin, even at doses 200-fold higher than the effective threshold. Its terminal half-life is approximately 2 hours.

Why This Pairing and Not Others

↑ Back to contents

The peptide community discusses many GH secretagogue combinations. Most of them are pharmacologically redundant, poorly rationalized, or both. The CJC-1295 (no DAC) + ipamorelin pairing is the exception because it is the one combination that activates two genuinely distinct receptor pathways with well-characterized synergy.

What makes it defensible:

• Complementary receptor targets. CJC-1295 (no DAC) activates the GHRH receptor (Gs-coupled, cAMP signaling). Ipamorelin activates GHS-R1a (Gq-coupled, calcium signaling). These are genuinely different intracellular cascades.
• Documented synergy. Published research demonstrates that simultaneous GHRH + GHS-R1a stimulation produces GH responses significantly greater than the sum of individual responses. GHRH increases the number of somatotrophs responsive to the GHS signal, while the GHS amplifies the magnitude of the pulse from each responding cell.
• Pulsatile profile. Both compounds have short half-lives (CJC-1295 no DAC ~30 min; ipamorelin ~2 hr), producing discrete GH pulses that mimic the body’s natural secretory pattern. This allows pituitary receptor resensitization between doses—a critical pharmacological requirement that sustained-elevation approaches (MK-677, CJC-1295 with DAC) do not provide.
• Clean side effect profile. Ipamorelin’s selectivity for GH over cortisol/prolactin eliminates the hunger, water retention, and cortisol elevation associated with GHRP-2 and GHRP-6.

The Pharmacology: How Dual-Pathway Stimulation Works

↑ Back to contents

Growth hormone release from pituitary somatotrophs is controlled by two opposing hypothalamic signals: GHRH (stimulatory) and somatostatin (inhibitory). The GH secretagogue stack amplifies the stimulatory side through two distinct mechanisms.

The GHRH receptor pathway (CJC-1295 no DAC): Binding activates Gs-coupled adenylate cyclase, raising intracellular cAMP, which activates protein kinase A. PKA phosphorylates downstream transcription factors (including CREB) that drive both GH gene transcription and granule exocytosis. This pathway primarily controls the amount of GH synthesized and available for release.

The GHS-R1a pathway (ipamorelin): Binding activates Gq-coupled phospholipase C, generating IP3 and diacylglycerol. IP3 mobilizes calcium from intracellular stores. The calcium spike triggers immediate GH granule fusion with the cell membrane—acute exocytosis. This pathway primarily controls the timing and magnitude of the GH pulse.

The crosstalk: Research published in PNAS demonstrated that GHRH is itself an agonist of GHS-R1a—meaning the GHRH receptor and ghrelin receptor physically interact at the membrane level. GHRH increases ghrelin binding capacity in a dose-dependent fashion. When a GHRH analog (like CJC-1295 no DAC) is present, the somatotroph becomes more responsive to the GHS-R1a agonist (ipamorelin). This is the mechanistic basis for the synergy: it is not simply additive; it involves receptor-level cooperativity.

Why the “no DAC” variant matters: CJC-1295 exists in two forms. The no-DAC version has a ~30-minute half-life and produces discrete GH pulses. CJC-1295 with DAC includes a Drug Affinity Complex (maleimide linker) that binds to serum albumin, extending the half-life to 6–8 days. The DAC variant produces sustained GHRH-receptor stimulation—not pulsatile. This matters because pituitary somatotrophs require troughs between pulses for GHS-R1a resensitization. Continuous stimulation blunts the pituitary response over time. The no-DAC variant preserves the pulsatile physiology that the GH axis depends on.

What the Evidence Actually Shows

↑ Back to contents

CJC-1295 (no DAC) Human Data

Clinical studies documented dose-dependent increases in mean plasma GH concentrations of 2–10 fold lasting 6+ days after a single injection, and mean plasma IGF-I concentration increases of 1.5–3 fold lasting 9–11 days. Pulsatile GH secretion was preserved even during continuous stimulation in the clinical research setting. These are well-characterized hormonal effects with real human PK data.

Ipamorelin Human Data

Phase I human trials confirmed ipamorelin’s selectivity: robust GH pulses without cortisol or prolactin elevation, even at suprapharmacological doses. Terminal half-life is approximately 2 hours. The compound produced dose-dependent GH release with a ceiling effect (the response plateaus at higher doses, which is consistent with receptor saturation—not a safety issue).

The Synergy Data

Published research (including human studies) demonstrated that co-administration of a GHRH analog and a GHS-R1a agonist produces GH responses significantly exceeding the additive sum. The PNAS study on GHRH as a GHS-R1a co-agonist provided the receptor-level mechanistic explanation. This synergy is among the best-characterized in peptide pharmacology.

The Gap: GH Elevation ≠ Outcomes

Here is where the evidence ends and the community extrapolation begins. No published randomized controlled trial has measured whether CJC-1295 (no DAC) + ipamorelin produces clinically meaningful changes in lean muscle mass, fat loss, recovery time, sleep quality, skin quality, or any of the other outcomes the community attributes to this stack. The hormonal effects are proven. The downstream outcomes are assumed.

This is not a trivial distinction. Exogenous GH therapy (actual recombinant hGH at pharmacological doses) produces measurable but modest body composition changes in clinical trials—and it comes with well-documented side effects (joint pain, edema, insulin resistance). The GH elevations from secretagogues are substantially lower than pharmacological GH replacement. Whether the secretagogue-level elevation crosses the threshold for meaningful tissue effects in healthy adults is an open question, not an established fact.

Common Claims versus Current Evidence

↑ Back to contents

Common Mistakes: What Not to Stack

↑ Back to contents

The peptide community frequently discusses GH secretagogue combinations that are pharmacologically redundant or counterproductive. Understanding why the CJC-1295 (no DAC) + ipamorelin pairing works requires understanding why other combinations do not.

MK-677 + ipamorelin: Both are GHS-R1a agonists. This is receptor redundancy—adding a second agonist at the same receptor does not produce synergy. MK-677 (note: MK-677 is not a peptide—it is a spiroindoline small molecule) has a 24-hour half-life and produces continuous GHS-R1a stimulation, which blunts pituitary responsiveness over time. Adding ipamorelin on top of continuous MK-677 exposure would target already-occupied receptors.

CJC-1295 (no DAC) + CJC-1295 (with DAC): Both target the GHRH receptor. The DAC variant’s 6–8-day half-life produces sustained GHRH-R stimulation. Adding the no-DAC variant on top introduces conflicting pharmacokinetic profiles—pulsatile on top of sustained—at the same receptor. The “no DAC” pulsatility rationale is nullified.

CJC-1295 (no DAC) + ipamorelin + MK-677: A common community “triple stack.” The CJC-1295 (no DAC) + ipamorelin pairing is defensible. Adding MK-677 introduces 24-hour GHS-R1a stimulation that undermines the pulsatile trough periods ipamorelin relies on for receptor resensitization. More is not more—see the More Is Not Always More guide.

Safety, Risks, and Monitoring

↑ Back to contents

Known pharmacological effects to monitor:

• Insulin sensitivity: GH elevation reduces peripheral insulin sensitivity and increases hepatic gluconeogenesis. Pulsatile GH (from this stack) produces intermittent insulin resistance during GH peaks with recovery during troughs—less metabolically costly than sustained GH elevation from MK-677, but still present. Fasting glucose should be monitored.
• The GLP-1 / GH conflict: If you are taking a GLP-1 receptor agonist (semaglutide, tirzepatide), be aware that GLP-1 agonism improves insulin sensitivity while GH elevation impairs it. These are pharmacological cross-purposes.
• Water retention: GH elevation promotes sodium and water retention. Mild peripheral edema and joint stiffness are common early effects that typically resolve. These are pharmacological, not pathological.
• IGF-1 elevation: Sustained IGF-1 elevation raises theoretical long-term concerns about cellular proliferation. Monitor IGF-1 levels. See the Which Biomarkers to Test guide.

Recommended monitoring panel: Fasting glucose, fasting insulin, HbA1c, IGF-1, and a comprehensive metabolic panel at baseline and 8–12 weeks. See the How to Design a Monitoring Protocol guide.

Legal and Regulatory Status

↑ Back to contents

Both compounds are WADA-prohibited at all times, in and out of competition. If you compete in any tested sport, this stack is not an option. See the FDA and WADA Regulatory Status guide.

Published Research Protocols

↑ Back to contents

Community Self-Experimentation Protocols

↑ Back to contents

For reconstitution technique, see the How to Reconstitute Lyophilized Peptides guide. For injection technique, see the Subcutaneous Injection Technique Guide.

Frequently Asked Questions

↑ Back to contents

Should I use CJC-1295 with DAC or without DAC?

Without DAC (also called Modified GRF 1-29). The no-DAC variant preserves pulsatile GH secretion, which is how the GH axis naturally operates. The DAC variant produces sustained GHRH-receptor stimulation that eliminates the trough periods somatotrophs need for receptor resensitization. For a full comparison, see the CJC-1295 with DAC pillar article.

Can I add MK-677 to this stack?

This is the most common question and the answer is no—not if your goal is optimized pulsatile GH. MK-677 is a continuous GHS-R1a agonist with a 24-hour half-life. Adding it to a pulsatile stack defeats the purpose. MK-677 also elevates fasting glucose in long-term clinical data and is not a peptide. See the MK-677 pillar article.

Why ipamorelin and not GHRP-2 or GHRP-6?

Selectivity. Ipamorelin is the only GHS-R1a agonist that does not elevate cortisol or prolactin. GHRP-2 raises prolactin and cortisol. GHRP-6 causes intense hunger through ghrelin-mediated pathways. Hexarelin is the most potent but also has the strongest cortisol effect and the most rapid tachyphylaxis (pituitary desensitization). Ipamorelin gives you the GH pulse without the side-channel hormonal noise.

How long until I see results?

There is no evidence-based answer. Community anecdotes commonly cite subtle changes (sleep quality, recovery) within 2–4 weeks, and more visible body composition changes at 3–6 months. These timelines are not from controlled studies and are confounded by concurrent training, nutrition, and placebo effects.

Can I take this with a GLP-1 medication?

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) improve insulin sensitivity. Elevated GH reduces peripheral insulin sensitivity. These are pharmacological cross-purposes. Pulsatile GH from this stack is less problematic than continuous MK-677 elevation, but the conflict exists. Monitor fasting glucose and HbA1c. Discuss with your prescribing physician.

Related Content

↑ Back to contents

Compound Articles:

• CJC-1295 (No DAC): What the Research Shows
• Ipamorelin: What the Research Actually Shows
• CJC-1295 with DAC: What the Research Shows
• MK-677 (Ibutamoren): What the Research Shows
• Sermorelin: What the Research Shows
• Hexarelin: What the Research Shows
• GHRP-2: What the Research Shows
• GHRP-6: What the Research Shows

Practical Guides:

• How to Reconstitute Lyophilized Peptides
• Subcutaneous Injection Technique Guide
• Half-Lives and Dosing Intervals
• Which Biomarkers to Test
• How to Design a Monitoring Protocol
• More Is Not Always More
• FDA and WADA Regulatory Status

Research Clusters:

• Growth Hormone Secretagogues Cluster

Summary and Key Takeaways

↑ Back to contents

The CJC-1295 (no DAC) + ipamorelin stack is the most pharmacologically defensible GH secretagogue combination available. The dual-pathway mechanism is well-characterized. The synergy between GHRH-R and GHS-R1a activation is confirmed in human research. Ipamorelin’s selectivity for GH over cortisol and prolactin is verified in Phase I data. Both compounds have human PK profiles.

The limitation is the gap between hormonal effects and clinical outcomes. Elevated GH and IGF-1 are surrogate endpoints, not clinical outcomes. No controlled trial has demonstrated that this stack produces meaningful changes in lean mass, fat mass, recovery time, or aging biomarkers in healthy adults. The community expects body composition results that the evidence has not confirmed.

If you are considering this stack, the honest assessment is: the mechanism is sound, the individual human data is real, the synergy is documented, the side effect profile (with ipamorelin specifically) is favorable compared to alternatives, and neither compound is FDA-approved. Whether the GH elevation translates to the outcomes you care about is an honest question that the research has not yet answered. Monitor your biomarkers. Do not assume hormonal changes equal clinical changes.